Vitamin D3 & K2: The Inseparable Calcium Partnership

Overview

The physiological interplay between cholecalciferol (Vitamin D3) and menaquinone (Vitamin K2) represents one of the most sophisticated, yet frequently misunderstood, regulatory axes in human metabolism. Within the rigorous educational framework of INNERSTANDIN, we must look beyond the reductionist paradigm that views vitamins as isolated micronutrients. Instead, D3 and K2 operate as an obligate biochemical dyad, orchestrating calcium homeostasis with surgical precision. While exogenous or cutaneous D3 acts as the master transcriptional regulator of intestinal calcium absorption—upregulating active transport proteins such as transient receptor potential vanilloid type 6 (TRPV6) and calbindin-D9k—it possesses no inherent mechanism to dictate the exact anatomical destination of the liberated ions. Without the biochemical oversight of K2, the systemic influx of calcium generated by optimized D3 status risks precipitating in undesirable soft-tissue matrices.

To comprehend the imperative nature of this partnership, one must examine the downstream protein targets activated by each micronutrient. Vitamin D3 transcriptionally induces the synthesis of matrix Gla protein (MGP) and osteocalcin, two quintessential vitamin K-dependent proteins (VKDPs). However, upon initial translation, these proteins exist in an inactive, uncarboxylated state. Herein lies the indispensable mechanistic role of Vitamin K2, specifically its long-chain menaquinone-7 (MK-7) isoform. MK-7 functions as an essential electron donor for the enzyme gamma-glutamyl carboxylase. This post-translational carboxylation adds a carboxyl group to specific glutamic acid residues on osteocalcin and MGP, inducing a conformational shift that grants them high binding affinity for divalent calcium ions.

Without sufficient K2 status—a vulnerability frequently exacerbated in the UK population due to seasonal UV-B deficits and low dietary intake of fermented foods—carboxy-osteocalcin remains functionally inert, impairing the proper hydroxyapatite crystallization required for optimal bone mineral density. Concurrently, uncarboxylated MGP fails to bind and neutralize free calcium within the tunica media of arterial walls, accelerating vascular calcification and arterial stiffening. Landmark epidemiological investigations, such as the Rotterdam Study published in the Journal of Nutrition, established a robust inverse correlation between long-term dietary intake of menaquinones and aortic calcification, as well as coronary heart disease mortality.

By unifying these pathways, INNERSTANDIN reveals that administering high-dose cholecalciferol in isolation is not merely suboptimal; it is biochemically incomplete. True calcium management requires the concurrent upregulation of transport mechanisms via D3 and the enzymatic activation of directing proteins via K2. This synergistic axis prevents ectopic calcification while ensuring targeted skeletal mineralization, embodying the uncompromising physiological synergy required for optimal human longevity and metabolic resilience.

The Biology — How It Works

To truly comprehend the physiological imperatives of calcium homeostasis, one must look past the simplistic dogma of isolated supplementation and examine the intricate biochemical choreography executed by vitamins D3 and K2. At the core of INNERSTANDIN's educational mandate is the exposure of reductionist nutritional paradigms; nowhere is this more evident than in the systemic handling of divalent calcium ions ($Ca^{2+}$). When cholecalciferol (D3) is ingested or synthesised via cutaneous 7-dehydrocholesterol conversion under UVB irradiation, it undergoes two sequential hydroxylations—first in the hepatic parenchyma into 25-hydroxyvitamin D3, and subsequently in the proximal tubules of the kidneys into its biologically active enantiomer, 1,25-dihydroxyvitamin D3 ($1,25(OH)2D3$), or calcitriol.

Calcitriol functions as a potent secosteroid hormone, binding to the nuclear vitamin D receptor (VDR) and heterodimerising with the retinoid X receptor (RXR) to modulate genomic transcription. In the enterocytes of the duodenum, this ligand-receptor complex upregulates the expression of transient receptor potential vanilloid type 6 (TRPV6) channels, calbindin-D9k intracellular transport proteins, and plasma membrane calcium-ATPase (PMCA1b), thereby drastically amplifying intestinal calcium absorption. Concurrently, calcitriol mobilises skeletal calcium reserves by inducing receptor activator of nuclear factor-κB ligand (RANKL) expression on osteoblasts, stimulating osteoclastogenesis to maintain serum normocalcaemia.

However, this biochemical cascade presents a profound clinical vulnerability. While Vitamin D3 successfully elevates serum bioavailable calcium, it possesses zero intrinsic regulatory capacity regarding where that mineral is ultimately deposited. Unchecked calcitriol activity inevitably leads to hypercalcaemia and ectopic mineralisation—the pathological precipitation of calcium phosphate crystals within the tunica media of arterial walls, cardiac valves, and renal parenchyma. This is where vitamin K2 (specifically the menaquinone-7, or MK-7, isoform) acts as the indispensable metabolic gatekeeper.

Vitamin K2 functions strictly as an essential cofactor for the enzyme gamma-glutamyl carboxylase. This post-translational modification converts specific glutamic acid (Glu) residues into gamma-carboxyglutamic acid (Gla) residues on two vital vitamin K-dependent proteins: osteoblast-derived osteocalcin and matrix Gla protein (MGP). Uncarboxylated osteocalcin remains biologically inert, floating idly in circulation; once carboxylated by K2-driven enzymatic action, it undergoes a conformational shift with a high-affinity binding profile for hydroxyapatite crystals, anchoring calcium firmly into the extracellular bone matrix to enhance structural mineral density.

Simultaneously, MGP—the most potent endogenous inhibitor of soft tissue calcification known to science—requires K2-dependent gamma-carboxylation to neutralize its inhibitory state. Without adequate MK-7 status, MGP remains uncarboxylated and inactive, failing to prevent vascular smooth muscle cells from undergoing osteochondrogenic transdifferentiation. Landmark epidemiological investigations, such as the Rotterdam Study published in The Journal of Nutrition, have demonstrated that high dietary intake of menaquinones significantly inverse-correlates with aortic calcification and all-cause cardiovascular mortality.

Therefore, viewing vitamin D3 in biological isolation is not merely scientifically incomplete; it is biochemically hazardous. The molecular axis of D3 and K2 represents a masterclass in physiological checks and balances: D3 opens the cellular floodgates for calcium acquisition, while K2 directs that mineral precisely into the osseous architecture while aggressively safeguarding the arterial tree from atherosclerotic calcification.

Mechanisms at the Cellular Level

At the cellular and molecular tiers, the physiological orchestration of calcium homeostasis is not governed by a single regulatory switch, but by a tightly coordinated biochemical relay between cholecalciferol (Vitamin D3) and the menaquinone family (Vitamin K2). When examined through an evidence-led lens, the administration of isolated Vitamin D3 without its K2 cofactor exposes a profound mechanistic flaw in traditional supplementation paradigms. Vitamin D3 acts primarily as the genomic upregulator of calcium absorption. Upon hepatic and subsequent renal hydroxylation into its active endocrine form, 1,25-dihydroxyvitamin D3 ($1,25(OH)2D3$), it binds to the vitamin D receptor (VDR) within the enterocytes of the small intestine. This ligand-receptor complex translocates to the nucleus, heterodimerises with the retinoid X receptor (RXR), and initiates the transcription of genes encoding calcium-transport proteins, most notably transient receptor potential vanilloid type 6 (TRPV6) for apical influx and calbindin-D9k for intracellular translocation. Consequently, serum ionized calcium levels rise significantly. However, $1,25(OH)2D3$ also transcriptionally activates osteocalcin and matrix Gla-protein (MGP)—two crucial calcium-binding proteins—yet these proteins are synthesized in an inactive, uncarboxylated state. This is where the biological imperative of Vitamin K2 becomes non-negotiable.

Vitamin K2, specifically in the long-chain menaquinone-7 (MK-7) isoform predominantly utilised in advanced biochemical formulations, functions as an obligatory enzymatic cofactor for gamma-glutamyl carboxylase. Within the endoplasmic reticulum of osteoblasts and vascular smooth muscle cells, MK-7 facilitates the post-translational carboxylation of osteocalcin's glutamic acid residues into gamma-carboxyglutamic acid (Gla). This specific structural modification induces a conformational change that grants osteocalcin a high binding affinity for hydroxyapatite crystals, anchoring calcium into the extracellular matrix of the bone and systematically increasing bone mineral density. Simultaneously, K2 carboxylates MGP, converting it into the most potent known endogenous inhibitor of vascular calcification. Uncarboxylated MGP floats idly in the vasculature, leaving arterial elastic fibres vulnerable to ectopic mineralisation.

As extensively documented in literature published in peer-reviewed repositories such as PubMed and the Lancet, decoupling these two micronutrients risks pathological mineral shifting. Without adequate MK-7 to drive carboxylation, the supraphysiological calcium influx mediated by VDR activation lacks directional guidance. Rather than integrating into the skeletal architecture, surplus calcium precipitates into the tunica media of arterial walls, accelerating vascular stiffening and endothelial dysfunction. Within the rigorous research frameworks upheld by INNERSTANDIN, we recognise that calcium utilisation is entirely vector-dependent. D3 provides the transport velocity, while K2 provides the spatial targeting. Disrupting this synergy converts a therapeutic bone-protective protocol into an accelerating factor for cardiovascular calcification, proving that biological efficacy at the cellular scale relies wholly on stoichiometric balance.

Environmental Threats and Biological Disruptors

Modern physiological homeostasis faces unprecedented disruption from environmental toxins, industrial byproducts, and widespread pharmacological interventions that systematically compromise the delicate enzymatic pathways governing fat-soluble vitamin metabolism. At INNERSTANDIN, our analysis of contemporary toxicological literature reveals that persistent organic pollutants (POPs), endocrine-disrupting chemicals (EDCs), and specific pharmaceutical classes actively interfere with the cytochrome P450 enzyme superfamilies responsible for hydroxylating cholecalciferol into its active endocrine form, calcitriol. When these environmental stressors sabotage hepatic and renal hydroxylation cascades, systemic calcium regulation is immediately thrown into profound disarray, precipitating a cascade of pathological calcification in vascular beds alongside concurrent osteoclast-mediated bone demineralisation.

Endocrine disruptors such as polychlorinated biphenyls (PCBs), phthalates, and bisphenols exert a profound antagonistic effect on the pregnane X receptor (PXR) and the vitamin D receptor (VDR) heterodimer complex. Research published in toxicology and endocrinology journals demonstrates that these xenobiotic compounds upregulate CYP24A1—the catabolic enzyme responsible for degrading active 1,25-dihydroxyvitamin D3 into inactive calcitroic acid—thereby inducing functional vitamin D deficiency regardless of adequate dermal synthesis or oral supplementation. Concurrently, the ubiquitous presence of glyphosate in Western agricultural supply chains chelates essential divalent cations, including the magnesium co-factors vital for activating the protein kinase cascades required for both vitamin D receptor binding and vitamin K-dependent gamma-glutamyl carboxylase activity. Without sufficient intracellular magnesium, cholecalciferol and menaquinone-7 cannot effectively orchestrate calcium ion (Ca2+) flux, leaving biological tissues vulnerable to ectopic mineralization.

Furthermore, pharmaceutical interventions frequently exacerbate this biochemical vulnerability. Chronic administration of proton pump inhibitors (PPIs) and broad-spectrum glucocorticoids impairs intestinal calcium absorption and accelerates vitamin D catabolism, while standard clinical management often relies solely on isolated cholecalciferol supplementation. As toxicological data underscores, introducing high-dose vitamin D3 in an environment saturated with endocrine disruptors—and deficient in menaquinone-7 (Vitamin K2)—drives a dangerous biochemical paradox. Unmitigated calcium influx, stimulated by unchecked cholecalciferol signalling in the absence of K2-activated matrix Gla protein (MGP) and osteocalcin carboxylation, results in accelerated arterial stiffening and nephrocalcinosis.

In the UK context, where suboptimal winter solar zenith angles already limit cutaneous pre-vitamin D3 synthesis, the compounding burden of industrial xenobiotics creates a syndemic of subclinical deficiency and tissue calcification. Public health paradigms that view nutrient status through a reductionist lens fail to account for these multi-factorial environmental stressors. Mitigating this systemic threat requires a rigorous, mechanistic understanding of how biological disruptors hijack fat-soluble vitamin metabolism, reinforcing the absolute necessity of a dual D3 and K2 intervention strategy to restore proper calcium partitioning and vascular resilience.

The Cascade: From Exposure to Disease

To fully comprehend the physiological imperatives governing calcium homoeostasis, one must trace the biochemical cascade originating from dermal exposure to ultraviolet B (UVB) radiation and project its trajectory through to systemic pathology. When cutaneous 7-dehydrocholesterol absorbs UVB photons within the 290–315 nm spectrum, a thermal isomerisation yields previtamin D3, which rapidly equilibrates into cholecalciferol (Vitamin D3). As documented extensively in literature featured across The Lancet, this biologically inert precursor undergoes two sequential hepatic and renal hydroxylations. First, hepatic microsomal 25-hydroxylases convert cholecalciferol into 25-hydroxyvitamin D3 [25(OH)D], the primary circulating storage form. Subsequently, renal and extra-renal CYP27B1-mediated 1$\alpha$-hydroxylase action yields 1,25-dihydroxyvitamin D3 [$1,25(OH)_2D$], the potent secosteroid hormone that binds the nuclear vitamin D receptor (VDR). Upon heterodimerisation with the retinoid X receptor (RXR), this complex modulates the transcription of hundreds of genes explicitly tailored to upregulate active intestinal calcium absorption via transient receptor potential vanilloid type 6 (TRPV6) channels and calbindin-D9k.

However, this is where a profound physiological decoupling occurs—one that traditional medicine has historically overlooked. While $1,25(OH)_2D$ aggressively drives serum calcium levels upward, it simultaneously induces the transcription of matrix Gla protein (MGP) and osteocalcin, both of which require post-translational carboxylation to become functionally competent. This is the exact biochemical juncture where Vitamin D3's autonomous journey terminates in pathological hazard, and the absolute necessity of Vitamin K2 (menaquinone, specifically the long-chain MK-7 variant) becomes immutable. Without sufficient K2 acting as an essential cofactor for gamma-glutamyl carboxylase, osteocalcin remains uncarboxylated (ucOC) and incapable of anchoring free calcium ions into the hydroxyapatite crystal lattice of the extracellular bone matrix. Concurrently, uncarboxylated MGP fails to inhibit ectopic mineralisation within the tunica media of arterial walls and heart valves.

Clinical data indexed in PubMed underscore the grim epidemiological fallout of this biochemical uncoupling. In populations deficient in synergistic menaquinones, unchecked calcium mobilisation driven solely by high-dose Vitamin D supplementation bypasses skeletal architecture. Instead, it precipitates progressive vascular calcification, dramatically increasing arterial stiffness, pulse wave velocity, and systemic pulse pressure. Within UK cohorts, where subclinical Vitamin D insufficiency intersects with modern diets severely depleted of fermentation-derived menaquinones, this cascade manifests as an accelerated cardiovascular risk profile running parallel to bone mineral density loss.

At INNERSTANDIN, our critical appraisal of the literature reveals that viewing these micronutrients in isolation is not merely scientifically obsolete; it is clinically hazardous. The molecular cascade initiated by sun exposure demands dual execution: Vitamin D3 builds the circulating ionic capacity, while Vitamin K2 enforces strict spatial governance, directing calcium away from soft-tissue calcification and exclusively into osseous architecture. Disrupting this inseparable partnership triggers a pathological domino effect where attempts to strengthen the skeletal system paradoxically calcify the cardiovascular network.

What the Mainstream Narrative Omits

For decades, public health messaging—including guidelines issued by the UK Scientific Advisory Committee on Nutrition (SACN)—has reduced calcium homeostasis and skeletal integrity to a simplistic linear equation: consume sufficient calcium and maintain adequate cholecalciferol (Vitamin D3) status to ensure intestinal absorption. This reductionist paradigm completely omits the biochemical reality of vascular biology. Cholecalciferol does not possess intrinsic directional intelligence; its primary physiological role is to upregulate the active transcellular and passive paracellular absorption of calcium across the enterocyte brush border, alongside the synthesis of calcium-binding proteins. Left uncounterbalanced, a high-D3 state aggressively elevates circulating ionized calcium. Without the concurrent presence of menaquinone-7 (Vitamin K2), this liberated calcium becomes an untethered liability within the systemic circulation.

The mainstream narrative consistently fails to articulate that Vitamin D3 acts merely as the gatekeeper of calcium influx, whereas Vitamin K2 serves as the molecular traffic controller determining its terminal destination. At the enzymatic level, K2 functions as an essential co-factor for the gamma-glutamyl carboxylase enzyme. This carboxylase is mandatory for activating two critical vitamin K-dependent proteins: osteoblast-derived osteocalcin, which chemically anchors ionized calcium into the hydroxyapatite crystal lattice of the bone matrix, and matrix Gla-protein (MGP), the most potent endogenous inhibitor of soft tissue calcification known to human physiology. When MGP remains uncarboxylated due to sub-optimal K2 status—a widespread issue exacerbated by modern Western diets and refined vegetable oils—it cannot bind calcium ions.

Consequently, relying solely on high-dose cholecalciferol supplementation without adequate menaquinone co-ingestion paradoxically accelerates vascular senescence. Peer-reviewed literature indexed in PubMed demonstrates that uncarboxylated MGP correlates directly with arterial stiffening, endothelial dysfunction, and the atherogenic calcification of the tunica media. As calcium precipitates within the elastic lamellae of the arterial tree, pulse wave velocity increases, elevating cardiovascular risk independent of traditional lipid markers. Furthermore, populations across the United Kingdom frequently present with subclinical K2 insufficiencies due to the decline of grass-fed animal products and fermented foods in the national diet. At INNERSTANDIN, our critical appraisal of the literature reveals that viewing these micronutrients in isolation is an outdated pharmacological fallacy; D3 and K2 operate as an obligate, synergistic dyad where uncoupling them transforms a bone-protective protocol into a cardiovascular hazard.

The UK Context

To innerstand the acute physiological vulnerability of the British population to calcium misregulation, one must first examine the interplay between high-latitude geography, socio-environmental factors, and molecular biology. According to epidemiological data published in The Lancet and monitored by the Scientific Advisory Committee on Nutrition (SACN), the United Kingdom faces a pervasive, low-grade public health crisis regarding Vitamin D3 (cholecalciferol) status. Between the months of October and March, the zenith angle of the sun in the UK prohibits UVB photons from penetrating the ozone layer at the wavelengths required (290–315 nm) for cutaneous previtamin D3 synthesis via the photolysis of 7-dehydrocholesterol in the stratum basale. Consequently, endogenous synthesis drops to absolute zero for half the year, rendering the population entirely dependent on hepatic stores, fortified foodstuffs, and supplementation.

However, addressing this widespread cholecalciferol deficit through D3 monotherapy alone introduces a profound biochemical hazard, a reality frequently overlooked in mainstream nutritional guidelines. When high-dose Vitamin D3 is ingested, it upregulates the intestinal transcription of calbindin-D9k and TRPV6 channels, drastically increasing active calcium absorption from the gut. In a population with a high baseline prevalence of subclinical Vitamin K2 (menaquinone) deficiency—stemming from a modern Western diet deficient in fermented foods, grass-fed ruminant fats, and natto—this surge in unshielded serum calcium encounters a severe lack of carboxylation capacity.

Without adequate menaquinone-7 (MK-7) or menaquinone-4 (MK-4), the extrahepatic Gla-proteins, specifically matrix Gla-protein (MGP) and osteocalcin, remain undercarboxylated and functionally inert. MGP serves as the primary biological inhibitor of arterial calcification; when uncarboxylated, vascular smooth muscle cells undergo osteogenic transition, accelerating vascular stiffening and endothelial dysfunction. Concurrently, uncarboxylated osteocalcin fails to bind hydroxyapatite crystals effectively within the bone matrix, decoupling serum calcium elevation from true skeletal mineralization.

UK clinical data reveals that despite widespread public health campaigns promoting dairy consumption for skeletal integrity, cardiovascular calcification metrics remain stubbornly high. This paradox is directly explained by the institutional failure to recognise the D3-K2 axis as an obligatory biochemical dyad. As detailed in peer-reviewed literature indexed on PubMed, restoring systemic calcium homeostasis requires the simultaneous activation of D3-mediated intestinal absorption and K2-mediated enzymatic carboxylation. For the British populace, navigating high-latitude winters demands an evidence-led paradigm shift: abandoning isolated vitamin supplementation in favour of synchronized D3 and K2 protocols designed to direct calcium precisely into the osseous matrix while safeguarding the arterial tree from pathological mineralization.

Protective Measures and Recovery Protocols

Therapeutic intervention involving cholecalciferol (D3) and menaquinone (K2) demands precision, particularly when addressing subclinical arterial calcification, osteopenia, or managing the iatrogenic risks associated with high-dose vitamin D monotherapy. As established in biochemical literature, unmitigated supplementation with cholecalciferol upregulates intestinal calcium absorption via the calbindin-D9k transport protein. However, without adequate menaquinone-7 (MK-7) to carboxylate osteocalcin and Matrix Gla Protein (MGP), this mobilized calcium frequently precipitates within the tunica media of vascular walls and renal parenchyma. Clinical recovery protocols and protective measures must therefore prioritize synergistic stoichiometry over isolated nutrient administration.

To reverse or halt vascular stiffening induced by historical calcium or high-dose D3 monotherapy, clinical trials referenced in databases such as PubMed demonstrate that daily regimens must incorporate MK-7 at dosages ranging from 180 to 360 micrograms, alongside standardized cholecalciferol protocols. MGP activation follows a sigmoidal dose-response curve; standard Recommended Daily Allowances (RDAs) are frequently insufficient to carboxylate the inactive desphospho-uncarboxylated MGP (dp-ucMGP) pool fully. By restoring adequate MK-7 status, the Gla residues on MGP achieve high-affinity binding capacity for free calcium ions, effectively sequestering them away from endothelial matrices and directing them toward hydroxyapatite crystal formation within the osteoid matrix.

Furthermore, protective strategies must account for individual genetic polymorphisms, specifically within the vitamin D receptor (VDR) gene and CYP2R1/CYP27A1 hydroxylase enzymes, which dictate individual metabolic conversion rates. Within the UK population—where winter-time solar zenith angles preclude cutaneous synthesis of cholecalciferol—baseline biochemical screening should routinely measure 25-hydroxyvitamin D [25(OH)D], serum ionized calcium, parathyroid hormone (PTH), and plasma dp-ucMGP. Elevated dp-ucMGP serves as a sensitive biomarker for functional K2 deficiency, signaling an immediate need for recovery protocols that adjust the D3-to-K2 ratio.

For individuals undergoing long-term glucocorticoid therapy or presenting with advanced metabolic syndrome, the acceleration of vascular calcification is particularly pronounced due to suppression of osteoblastogenesis and downregulation of local K-dependent carboxylase enzymes. Here, INNERSTANDIN emphasizes that protective clinical protocols cannot rely on vitamin D alone. Co-administration of MK-7 mitigates the vascular toxicity of hypercalcemia by ensuring that the upregulated synthesis of osteocalcin—triggered by 1,25-dihydroxyvitamin D—is matched by an equivalent capacity to carboxylate and activate the protein. This biochemical equilibrium prevents ectopic mineralization, preserves arterial compliance, and optimizes bone mineral density accrual, reaffirming that the therapeutic window of cholecalciferol is entirely dependent on the concurrent presence of menaquinone.

Summary: Key Takeaways

Current biochemical paradigms demand a rigorous re-evaluation of isolated micronutrient supplementation, specifically regarding the synergistic nexus of Cholecalciferol (Vitamin D3) and Menaquinone (Vitamin D-dependent Vitamin K2). As evidenced by extensive peer-reviewed literature indexed in PubMed, unmitigated D3 administration—while vital for upregulating intestinal calcium absorption via calbindin-D9k transcription—presents a profound physiological paradox in the absence of adequate K2 co-factors. Without sufficient menaquinone status (predominantly the MK-7 isoform) to carboxylate and thereby activate osteoblast-derived osteocalcin and extra-hepatic matrix Gla-protein (MGP), systemic calcium remains prone to ectopic precipitation. This manifests as vascular calcification, arterial stiffening, and microvascular pathology, directly contradicting the putative cardiovascular benefits traditionally associated with vitamin optimization.

At INNERSTANDIN, our exhaustive analysis of clinical outcomes underscores that D3 and K2 operate as an obligate biological dyad: D3 orchestrates systemic mineral influx, whilst K2 acts as the molecular traffic controller, carboxylation-dependent and precision-targeted, ensuring divalent calcium ions are channeled away from soft tissues and bio-densified into the hydroxyapatite matrix of the skeletal architecture. Within the UK demographic context—where sub-optimal vitamin D statuses are endemic due to high latitude and seasonal irradiance deficits—blind supplementation protocols lacking K2 represent an incomplete clinical strategy. True physiological homeostasis and vascular integrity necessitate the simultaneous optimisation of both pathways, solidifying the D3-K2 partnership as a cornerstone of advanced metabolic resilience.